Ovarian Suppression May Not Benefit Premenopausal Breast Cancer Patients Over 40

Administering ovarian function suppression after chemotherapy may not be imperative for premenopausal patients aged over 40 years who have high-risk early hormone receptor-positive breast cancer, according to a retrospective cohort study published in BMC Women’s Health. Researchers evaluated clinical outcomes among patients treated at Sun Yat-Sen University Cancer Center to address whether this widely utilized intervention provides measurable therapeutic benefits in individuals who frequently experience chemotherapy-induced ovarian dysfunction. In their comparative analyses, the addition of ovarian suppression therapy failed to produce statistically significant differences in either disease-free survival or overall survival when compared against chemotherapy regimens administered without subsequent ovarian suppression.

Ovarian function suppression represents a common therapeutic strategy for premenopausal patients diagnosed with hormone receptor-positive breast cancer, yet its true efficacy has remained uncertain among individuals prone to chemotherapy-induced ovarian impairment. To investigate this issue, the investigators conducted a comprehensive retrospective investigation examining whether the suppression of ovarian function genuinely influences long-term oncologic outcomes in this mature premenopausal population.

The retrospective investigation evaluated a total cohort of 1,386 premenopausal women over 40 years old who were diagnosed with high-risk early hormone receptor-positive breast cancer and underwent chemotherapy at Sun Yat-Sen University Cancer Center between January 2010 and December 2017. Within this cohort, 258 patients received ovarian function suppression as part of their therapeutic management, whereas 1,128 patients did not receive suppression therapy. To mitigate the selection bias inherent to observational retrospective data, the researchers implemented propensity score matching, establishing well-balanced comparative groups for survival assessments.

Following propensity score matching, the investigators conducted Kaplan-Meier survival analyses to evaluate disease-free survival and overall survival across the matched cohorts. The five-year disease-free survival rate reached 82.4 percent in the non-ovarian function suppression group and 80.0 percent in the ovarian function suppression group, demonstrating no statistically significant divergence between the two treatment strategies (p = 0.62). Similarly, the corresponding five-year overall survival rates were 90.9 percent for patients managed without ovarian suppression and 92.3 percent for those who underwent suppression therapy (p = 0.50). These comparable survival metrics indicated that routinely adding ovarian suppression did not yield a measurable survival advantage in the matched population.

The investigative team monitored serum hormone levels to delineate patterns of ovarian function recovery among participants who did not receive ovarian function suppression. Within this unsuppressed cohort, only 8.86 percent of patients—representing 100 out of 1,128 individuals—demonstrated ovarian function recovery following completion of chemotherapy. Crucially, when researchers evaluated long-term outcomes, the disease-free survival (p = 0.79) and overall survival (p = 0.35) observed in the ovarian function recovery group remained comparable to the rates documented among patients who experienced permanent chemotherapy-induced menopause, indicating that spontaneous recovery did not broadly diminish clinical survival.

Further subgroup investigations within the ovarian function recovery cohort demonstrated that specific temporal dynamics were associated with poorer survival outcomes. Patients who experienced an ovarian function recovery interval time of 10 months or less, as well as those with an ovarian function recovery duration time exceeding 12 months, exhibited inferior disease-free survival and overall survival. Nevertheless, the study revealed that only a very small fraction of patients over forty years of age met these risk criteria, with just 3.45 percent (39 out of 1,128 patients) experiencing a recovery interval of 10 months or less, and only 3.98 percent (45 out of 1,128 patients) exhibiting a recovery duration exceeding 12 months after chemotherapy.

Based on these findings, the study authors concluded that the administration of ovarian function suppression after chemotherapy may not be imperative for premenopausal patients aged over 40 years presenting with early high-risk hormone receptor-positive breast cancer. Because the vast majority of patients in this age bracket develop persistent ovarian dysfunction from chemotherapy, and because post-chemotherapy ovarian function recovery occurred in under nine percent of unsuppressed individuals without altering overall survival trajectories, universal suppression therapy may not provide essential clinical utility for this specific demographic.

Subject of Research: Ovarian function suppression efficacy in premenopausal breast cancer patients over 40

Article Title: Ovarian function suppression is not indispensable for early premenopausal breast cancer patients aged over 40 years after chemotherapy

Article References: Zhang, K., Xian, J., Zhao, Z., Sun, Y., Wang, Y., Wu, H., Du, T., Xiao, X., Wei, W., Xie, X., Wang, X., & Tang, J. (2026). Ovarian function suppression is not indispensable for early premenopausal breast cancer patients aged over 40 years after chemotherapy. BMC Women's Health. https://doi.org/10.1186/s12905-026-05079-6

Image Credits: AI Generated

DOI: 10.1186/s12905-026-05079-6

Keywords: breast cancer, ovarian function suppression, chemotherapy, premenopausal patients, disease-free survival, overall survival, oncology, endocrinology, Ovarian, function, suppression, indispensable